The evolving methodologies for characterizing HER2 status, particularly through the combined use of immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH), have significantly refined our understanding of HER2 in breast cancer. Here, ERBB2 is linked to breast carcinoma.